Significant milestone for the Dementia with Lewy Bodies community: new DLB trials moving to Phase 3; CervoMed aligned with the FDA on a registration path for neflamapimod.
#Dementia #LewyBodyDementia #DLB #ClinicalTrials #Phase3 #Neflamapimod

@alzassociation.bsky.social critically support research to fulfill their mission of a world without Alzheimer's through:
• SEEDING new ideas
• SPEEDING development of new therapies
• SCALING
Over $450M+ funding across 56 countries, increasing their support for early-career researchers.

Empowering the care team makes a difference in #dementia. @Alz_Journals: InDePendent trial found that tailored care by qualified nurses provided for people living with dementia led to 74% fewer unmet needs and higher quality of life, cost-effectively #dementiacare #careteam

Texas Proposition 14, a game-changer to fight Alzheimer’s and other dementias. #TXProp14 would fund the Dementia Prevention and Research Institute of Texas (DPRIT) with a $3 billion investment from the state's budget surplus.
Vote YES #AlzheimersResearch #TexasElections #DPRIT www.alz.org/yeson14

Representing #LBDA and @houstonmethodist.bsky.social at the #HAPS Engage.Educate.Empower. Symposium

Proud to be designated an LBDA Research Center of Excellence.
This placard represents our commitment to patients and families we serve, and our dedication to advancing a cure. A huge thank you to our dedicated team and the entire LBD community.
#LewyBodyDementia #DementiaResearch #LBDA #EndLBD

Table. Broker Financial Incentives and Possible Reforms

When they become eligible for Medicare, beneficiaries must choose to enroll in Medicare Advantage (MA) or traditional Medicare.

This Viewpoint discusses the differences between MA and traditional Medicare. https://ja.ma/3FzVLc0

Exciting work form Borghammer's lab describing sympathetic and parasympathetic involvement and brain vs body first progression in #LBD #PD #DLB further read in bit.ly/41N13Z2

SHIMMER COG1201 #CT1812 showed in mid-moderate #DLB phase 2 exploratory positive results in NPI caregiver burden, underpowered results favoring cognitive CDR, ADL, MDS-UPDRS III for CT1812

Well deserved rising star awards #ILBDC #DLB

Broad expertise panel discussion in #DLB #Staging including #ATN #NSD-ISS #SynNeurGe and @LBDAssoc

Ian McKeith was just surprised with the announcement and being awarded the first DLB lifetime award at #ILBDC #DLB

Thank you to @rorycj.bsky.social for his support on World Lewy Body Day!

#dementia

World Lewy Body Dementia Day 2025: Shining a spotlight on the “unknown” dementia - ITN Business This Sunday 28th January marks the first World Lewy Body Day, a new awareness day that aims to shine a light on Lewy body dementia (LBD).

Looking forward to World Lewy Body Day tomorrow!

Thank you to ITN Business for sharing this on the eve of our big day.

Please help us tomorrow by sharing our posts to try to get the world to understand that dementia doesn't always mean Alzheimer's.

#worldlewybodyday #wlbd2025 #lewybodydementia

Feeling like a late and quiet Christmas day on the way to work in Houston.

Cognitive decline profiles associated with lewy pathology in the context of Alzheimer’s disease neuropathologic change - Alzheimer's Research & Therapy Background Alzheimer’s disease neuropathologic change (ADNC) and Lewy pathology (LP) often coexist in cognitively impaired individuals. These pathologies’ relative distribution and severity may modify...

See our new paper on the impact of Lewy and Alzheimer co-pathology on cognitive and clinical changes #DLBAwareness #Alzheimers #EndDementia #CoPathologies bit.ly/3DU8WDT

IMPACT AD; training program for professionals interested in Alzheimer's clinical trials. Overview of all clinical trials aspects, proposals reviews, career advice, and mentoring. Join the program and become an alumni. #IMPACT_AD #Alzheimers #ClinicalTrials impact-ad.org